{"DataElement":{"publicId":"2936640","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy Myelodysplastic Syndrome And/Or Myeloproliferative Neoplasm Status Type","preferredDefinition":"A description of the best response to therapy for myelodysplastic syndrome and/or myeloproliferative neoplasm.","longName":"2946463v1.0:2936620v1.5","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2936620","version":"1.5","preferredName":"Myelodysplastic Syndrome And/Or Myeloproliferative Neoplasm Status Type","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines.  The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia.  It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy.  (WHO, 2001)_Used to indicate that either or both of two items or options may be valid._A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_A condition or state at a particular time._Type; a subdivision of a particular kind of thing.","longName":"2936620v1.5","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Complete remission (CR)","valueDescription":"Complete remission","ValueMeaning":{"publicId":"3298538","version":"1","preferredName":"Complete remission","longName":"3298538","preferredDefinition":"Requires all of the following, maintained for greater than or equal to 4 weeks: 1) bone marrow evaluation: less than 5 percent myeloblasts with normal maturation of all cell lines; 2) peripheral blood evaluation: hemoglobin greater than or equal to 11 g/dL untransfused and without erythropoietin support; ANC greater than or equal to 1000 / mmE3 without myeloid growth factor support; platelets greater than or equal to 100 x 10E9/L without thrombopoietic support; 0 percent blasts.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04926F9-91D1-5A02-E040-BB89AD4359EA","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6ED7-D8EA-E050-BB89AD432E12","beginDate":"2009-10-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"Continued complete remission (CCR)","valueDescription":"Continued complete remission","ValueMeaning":{"publicId":"3691833","version":"1","preferredName":"Continued complete remission","longName":"3691833","preferredDefinition":"The patient had achieved a complete response; received more therapy and continued in complete response.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"D71B7975-BFCB-8894-E040-BB89AD4376CE","latestVersionIndicator":"Yes","beginDate":"2013-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-03-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6EE1-D8EA-E050-BB89AD432E12","beginDate":"2013-03-04","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"Hematologic improvement (HI)","valueDescription":"Hematologic improvement","ValueMeaning":{"publicId":"3298539","version":"1","preferredName":"Hematologic improvement","longName":"3298539","preferredDefinition":"Requires one measurement of the following, maintained for greater than or equal to 8 weeks without ongoing cytotoxic therapy; specify which cell line was measured to determine HI response: 1) HI-E: hemoglobin increase of greater than or equal to 1.5 g/dL untransfused; for RBC transfusions performed for Hgb less than or equal to 9.0, reduction in RBC units transfused in 8 weeks by greater than or equal to 4 units compared to the number of units transfused in the 8 weeks prior to treatment 2) HI-P: for pre-treatment platelet count of greater than 20 x 10E9/L, platelet absolute increase of greater than or equal to 30 x 10X9/L; for pre-treatment platelet count of less than 20 x 10E9/L, platelet absolute increase of greater than or equal to 20 x 10E9/L and greater than or equal to 100 percent from pre-treatment level 3) HI-N: neutrophil count increase of greater than or equal to 100 percent from pre-treatment level and an absolute increase of greater than or equal to 500 / mm3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B04926F9-91F3-5A02-E040-BB89AD4359EA","latestVersionIndicator":"Yes","beginDate":"2011-10-27","endDate":null,"createdBy":"NYCHM","dateCreated":"2011-10-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6EEB-D8EA-E050-BB89AD432E12","beginDate":"2009-10-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"No response (NR) / stable disease (SD)","valueDescription":"No response / stable disease","ValueMeaning":{"publicId":"3124192","version":"1","preferredName":"No response / stable disease","longName":"3124192","preferredDefinition":"Does not meet the criteria for at least hematologic improvement, but no evidence of disease progression","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BFEF234-3675-944B-E040-BB89AD4366C3","latestVersionIndicator":"Yes","beginDate":"2010-07-22","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6EF5-D8EA-E050-BB89AD432E12","beginDate":"2009-10-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"Negation Assessment","ValueMeaning":{"publicId":"3049794","version":"1","preferredName":"Negation Assessment","longName":"3049794","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: Having determined the value, significance, or extent of.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Assessment","conceptCode":"C25217","definition":"The final result of a determination of the value, significance, or extent of.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"836E0020-994D-2647-E040-BB89AD435E03","latestVersionIndicator":"Yes","beginDate":"2010-04-04","endDate":null,"createdBy":"CHILLIJ","dateCreated":"2010-04-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6EFF-D8EA-E050-BB89AD432E12","beginDate":"2011-10-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"Progression from hematologic improvement (Prog from HI)","valueDescription":"Progression from hematologic improvement","ValueMeaning":{"publicId":"3124193","version":"1","preferredName":"Progression from hematologic improvement","longName":"3124193","preferredDefinition":"Requires at least one of the following, in the absence of another explanation (e.g., infection, bleeding, ongoing chemotherapy, etc.): greater than or equal to 50 percent reduction from maximum response levels in granulocytes or platelets; reduction in hemoglobin by greater than or equal to 1.5 g/dL; transfusion dependence","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BFEF234-3698-944B-E040-BB89AD4366C3","latestVersionIndicator":"Yes","beginDate":"2010-07-22","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6F09-D8EA-E050-BB89AD432E12","beginDate":"2009-10-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"Relapse from complete remission (Rel from CR)","valueDescription":"Relapse from complete remission","ValueMeaning":{"publicId":"3124195","version":"1","preferredName":"Relapse from complete remission","longName":"3124195","preferredDefinition":"Requires at least one of the following: return to pre-treatment bone marrow blast percentage; decrease of greater than or equal to 50 percent from maximum response levels in granulocytes or platelets; transfusion dependence, or hemoglobin level greater than or equal to 1.5 g/dL lower than prior to therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BFEF234-36E1-944B-E040-BB89AD4366C3","latestVersionIndicator":"Yes","beginDate":"2010-07-22","endDate":null,"createdBy":"WHITES","dateCreated":"2010-07-22","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6F13-D8EA-E050-BB89AD432E12","beginDate":"2009-10-01","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"Never treated","valueDescription":"Never Therapeutic Procedure","ValueMeaning":{"publicId":"2685077","version":"1","preferredName":"Never Therapeutic Procedure","longName":"2685077","preferredDefinition":"Not ever; at no time in the past (or future).: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Never","conceptCode":"C70543","definition":"Not ever; at no time in the past (or future).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B83BB14-A509-653C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-02","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6F1D-D8EA-E050-BB89AD432E12","beginDate":"2011-10-27","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"Progression to AML","valueDescription":"Progression to AML","ValueMeaning":{"publicId":"3366809","version":"1","preferredName":"Progression to AML","longName":"3366809","preferredDefinition":"Greater than or equal to 20 percent blasts in the peripheral blood or bone marrow.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B7C44460-438C-29A4-E040-BB89AD4355C1","latestVersionIndicator":"Yes","beginDate":"2012-01-30","endDate":null,"createdBy":"ZHANGW","dateCreated":"2012-01-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6F27-D8EA-E050-BB89AD432E12","beginDate":"2011-11-18","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"},{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1068378F-6F31-D8EA-E050-BB89AD432E12","beginDate":"2014-03-13","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"ONEDATA","dateModified":"2015-03-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3946539","version":"1","preferredName":"Myelodysplastic Syndrome And/Or Myeloproliferative Neoplasm Status Type","preferredDefinition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001):Used to indicate that either or both of two items or options may be valid.:A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008):A condition or state at a particular time.:Something distinguishable as an identifiable class based on common qualities.","longName":"3946539v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myelodysplastic Syndrome","conceptCode":"C3247","definition":"A clonal hematopoietic disorder characterized by dysplasia and ineffective hematopoiesis in one or more of the hematopoietic cell lines. The dysplasia may be accompanied by an increase in myeloblasts, but the number is less than 20%, which, according to the WHO guidelines, is the requisite threshold for the diagnosis of acute myeloid leukemia. It may occur de novo or as a result of exposure to alkylating agents and/or radiotherapy. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"And/Or","conceptCode":"C48928","definition":"Used to indicate that either or both of two items or options may be valid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EA866B84-536D-61F2-E040-BB89AD432B31","latestVersionIndicator":"Yes","beginDate":"2013-11-06","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-11-06","modifiedBy":"ONEDATA","dateModified":"2013-11-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1068378F-6EC1-D8EA-E050-BB89AD432E12","latestVersionIndicator":"Yes","beginDate":"2009-08-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-03","modifiedBy":"NYCHM","dateModified":"2017-02-03","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964908","version":"1","longName":"2116r1: Myeloma Post-HSCT Data","context":"NHLBI"},{"publicId":"2964907","version":"1","longName":"2114r1: MDS Post-HSCT Data","context":"NHLBI"},{"publicId":"2964931","version":"1","longName":"2014r1: MDS Pre-HSCT Data","context":"NHLBI"},{"publicId":"3279271","version":"1","longName":"Disease Status","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"mds_post_bst_resp_hsct","type":"NMDP_FN","context":"NHLBI"},{"name":"mds_base_tx_best_resp","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"MDSpre_therapy_multi_mds_alt_best_resp","type":"NMDP_FN","context":"NHLBI"},{"name":"MDSpost_best_resp","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the best response of","type":"Preferred Question Text","description":"What was the best response of myelodysplastic/myeloproliferative disease to therapy?","url":null,"context":"NHLBI"},{"name":"What was the best response to HSCT?","type":"Alternate Question Text","description":"What was the best response to HSCT?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2936640","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis > AssessedResultRelationship > PerformedObservation > PerformedClinicalinterpretation.value = \"best result\" AND PerformedDiagnosis.value = \"myelodysplastic/myeloproliferative\" AND PerformedDiagnosis > PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Administer Hematopoietic Stem Cell Product{transplantation}\"","url":null,"context":"NHLBI"},{"name":"What was the best response to HCT?","type":"Alternate Question Text","description":"What was the best response to HCT?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Alternate Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"},{"name":"What was the best response to HCT?","type":"Application Standard Question Text","description":"What was the best response to HCT?","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"723A02A5-A4F0-8571-E040-BB89AD437FC0","latestVersionIndicator":"Yes","beginDate":"2009-08-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-08-28","modifiedBy":"KUMMEROA","dateModified":"2021-06-17","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}